Fundamental Analysis of NOVO INTEGRATED SCIENCES INC(NASDAQ:NVOS) stock

Fundamental Rating

We assign a fundamental rating of 1 out of 10 to NVOS. NVOS was compared to 113 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of NVOS have multiple concerns. NVOS does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

NVOS had negative earnings in the past year.

In the past year NVOS has reported a negative cash flow from operations.

In the past 5 years NVOS always reported negative net income.

NVOS had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

NVOS's Return On Assets of -68.87% is on the low side compared to the rest of the industry. NVOS is outperformed by 89.47% of its industry peers.

NVOS's Return On Equity of -244.36% is on the low side compared to the rest of the industry. NVOS is outperformed by 85.09% of its industry peers.

		Industry Rank	Sector Rank
ROA	-68.87%
ROE	-244.36%
ROIC	N/A

ROA(3y)-41.58%

ROA(5y)-27.97%

ROE(3y)-70.22%

ROE(5y)-45.76%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

NVOS has a better Gross Margin (37.68%) than 67.54% of its industry peers.

NVOS's Gross Margin has been stable in the last couple of years.

NVOS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	37.68%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.4%

GM growth 5Y0.48%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

NVOS does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for NVOS has been increased compared to 1 year ago.

The number of shares outstanding for NVOS has been increased compared to 5 years ago.

The debt/assets ratio for NVOS has been reduced compared to a year ago.

2.2 Solvency

NVOS has an Altman-Z score of -4.58. This is a bad value and indicates that NVOS is not financially healthy and even has some risk of bankruptcy.

The Altman-Z score of NVOS (-4.58) is worse than 84.21% of its industry peers.

A Debt/Equity ratio of 0.16 indicates that NVOS is not too dependend on debt financing.

NVOS's Debt to Equity ratio of 0.16 is fine compared to the rest of the industry. NVOS outperforms 70.18% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.16
Debt/FCF	N/A
Altman-Z	-4.58

ROIC/WACCN/A

WACC7.3%

2.3 Liquidity

A Current Ratio of 0.27 indicates that NVOS may have some problems paying its short term obligations.

With a Current ratio value of 0.27, NVOS is not doing good in the industry: 92.98% of the companies in the same industry are doing better.

A Quick Ratio of 0.22 indicates that NVOS may have some problems paying its short term obligations.

The Quick ratio of NVOS (0.22) is worse than 93.86% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.27
Quick Ratio	0.22

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 84.52% over the past year.

The Revenue has grown by 1106.87% in the past year. This is a very strong growth!

NVOS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.18% yearly.

EPS 1Y (TTM)84.52%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-635.41%

Revenue 1Y (TTM)1106.87%

Revenue growth 3Y16.95%

Revenue growth 5Y7.18%

Sales Q2Q%-4.2%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NVOS. In the last year negative earnings were reported.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

NVOS does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

NOVO INTEGRATED SCIENCES INC

NASDAQ:NVOS (11/5/2024, 8:00:01 PM)

After market: 0.1132 -0.04 (-24.53%)

0.15

-0.02 (-13.29%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Providers & Services

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap2.86M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-68.87%
ROE	-244.36%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	37.68%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.38

Health

		Industry Rank	Sector Rank
Debt/Equity	0.16
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	0.27
Quick Ratio	0.22
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)84.52%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next YN/A

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)1106.87%

Revenue growth 3Y16.95%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

NOVO INTEGRATED SCIENCES INC (NVOS)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens